Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02848872 · ClinicalTrials.gov registry record
Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 25
- Enrollment target
NCT02848872 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 25 participants.
The verdict
NCT02848872 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The hypothesis of this study is that functional tumor infiltrating lymphocyte (TIL) isolation from resected lung cancer specimens is feasible, allowing determination of tumor antigen-specific T cell reactivities. The primary objective of this study is to investigate the feasibility of isolating functional tumor infiltrating lymphocytes s(TILs) to determine tumor antigen-specific T cell re-activities in 30 resected lung tumor specimens. Successful isolation of TILs will be defined as collecting 1x10-6 viable, CD45+ mononuclear cells or greater from tumors containing \>/=1 gram of excess tissue. If successful isolation of TILs can be obtained from \>/= 66% of resected tumor specimens, the protocol will be considered feasible. The primary exploratory objective is to identify immunologic signatures that predict clinical outcomes from cytotoxic chemotherapy and/or immunotherapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-05 |
| Est. Completion | 2019-04-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02848872
The ClinicalTrials.gov registry entry for NCT02848872 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02848872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02848872 about?
NCT02848872 is a clinical study titled "Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer". The hypothesis of this study is that functional tumor infiltrating lymphocyte (TIL) isolation from resected lung cancer specimens is feasible, allowing determination of tumor antigen-specific T cell reactivities. The primary objective of this study is to investigate the feasibility of isolating func...
What is the current status of trial NCT02848872?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2016-05. Estimated completion is 2019-04-02.
Who is sponsoring clinical trial NCT02848872?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.